Trimiron

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trimiron

Quick Facts

Property Description
Active ingredients Desogestrel, Ethinyl Estradiol
Form Oral tablet
Pharmacological class Combination Hormonal Contraceptive (CHC)
Common use Prevention of pregnancy (Birth control)
Origin Synthetic (steroid hormones)

What Type of Medicine is Trimiron?

Trimiron is a synthetic, orally administered, prescription-only medication belonging to the pharmacological class of Combination Hormonal Contraceptives (CHC). This classification establishes it as a product containing two types of hormones, an estrogen and a progestin, designed for systemic administration to achieve the prevention of pregnancy. The product is manufactured as an oral tablet, the standard route of administration for this category of medication. The term "combination" is key, confirming the medication utilizes a balanced dual-hormone approach, which is clinically recognized for achieving reliable cycle control. The unique formulation of Desogestrel and Ethinyl Estradiol places this combination among the widely utilized oral contraceptives globally.

Composition: The Role of Desogestrel and Ethinyl Estradiol

The medication's composition features two distinct active ingredients: the progestin Desogestrel and the estrogen Ethinyl Estradiol. Both compounds are entirely synthetic steroid hormones, chemically engineered to modulate the body's natural reproductive cycle. Desogestrel is specifically designated a third-generation progestogen, a categorization that reflects its unique chemical structure and specific metabolic pathway, where it is converted into the active compound etonogestrel within the body. The dual component nature is essential, as the combination of synthetic estrogen and progestin acts synergistically to regulate the hormonal axis.

How the Combination Provides Contraception

The high-level purpose of Trimiron is to deliver highly effective contraception through a multi-layered physiological mechanism. The primary action is the inhibition of ovulation, effectively preventing the release of an egg from the ovary each month. The combined hormones also cause the cervical mucus to become significantly thicker, creating a physical barrier to sperm, and they additionally modify the uterine lining (endometrium), rendering it unreceptive to the implantation of a fertilized egg. These three actions ensure the medication provides dependable birth control as a routine, non-surgical method of family planning.

Regulatory References

  1. Oral Contraceptive Pills - StatPearls

What side effects are possible with Trimiron?

Possible Side Effects and Safety Information

Regulatory authorities classify the possible effects of Trimiron (Desogestrel / Ethinyl Estradiol) based on the physiological system affected and the frequency of occurrence as documented in official safety surveillance.

Common and Uncommon Adverse Reactions

The majority of documented adverse reactions are categorized as Very Common or Common and involve the Nervous System (Headache), Gastrointestinal Disorders (Nausea), and Reproductive System and Breast Disorders (Breast pain, Amenorrhea, or irregular bleeding). Other common effects include changes in mood and weight increase. Effects such as vomiting, fluid retention, decreased libido, and dermatological events like rash or urticaria are classified as Uncommon in official Summary of Product Characteristics (SmPC) documents.

Serious Adverse Reactions and Key Constraints

The most serious risks are classified as Rare but are highlighted in regulatory warnings. These include Venous Thromboembolism (VTE), such as deep vein thrombosis (DVT) and pulmonary embolism (PE), and Arterial Thromboembolism (ATE), encompassing stroke and myocardial infarction. The risk of these thromboembolic events is officially documented as being highest during the first year of use or upon re-initiation after a break of four weeks or more.

Population-specific constraints are integral to the safety profile. The medication is officially contraindicated for use in smokers aged 35 years and older due to a significantly increased risk of serious cardiovascular events. It is also restricted for individuals with a history of thromboembolic events or severe hepatic impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Trimiron (Desogestrel/Ethinyl Estradiol) classifies an acute overdose as generally not likely to be life-threatening, confirming that no serious harmful effects have been officially reported. This classification is consistent across multiple government health authorities.

Documented Overdose Manifestations

Overdose symptoms are characterized by hormonal manifestations, primarily affecting the reproductive and gastrointestinal systems. The most common signs documented in regulatory information include nausea and vomiting. An expected manifestation is the occurrence of withdrawal bleeding (slight vaginal bleeding). This bleeding is specifically noted to occur in females of all ages following an acute ingestion, including prepubertal girls, due to the high hormone concentration.

Emergency Response and Management

The regulatory guidance mandates specific actions regardless of the low acute toxicity profile. Immediate medical help must be sought right away upon any suspicion of overdose. This is achieved by contacting a Poison Control Center or Emergency Services for assessment and necessary monitoring. Treatment is limited to symptomatic and supportive measures because official labeling confirms that no specific antidote is known for this product. Management focuses on clinical observation and relief of the transient symptoms experienced until the elevated hormone levels subside.

Therapeutic Uses of Trimiron

What Trimiron Treats: Main Uses and Benefits

Trimiron (Trimetazidine) is applied across domains where additional symptomatic support is needed to help manage symptoms related to compromised circulatory function. The medication is indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris.

It is commonly used in conditions characterized by periods of heightened symptoms such as chest discomfort during physical activity, functional limitations, or general physiological strain. It is relevant for easing symptoms related to discomfort that may interfere with daily functioning. This symptomatic assistance provides support that helps ease the overall symptom burden during symptomatic periods. It is generally applied in clinical settings relevant when supportive symptom management is appropriate for conditions involving episodic or fluctuating manifestations.


Quick Fact: Supportive Management for Circulatory Discomfort Trimiron is commonly used to help with symptoms related to organ-specific functional stress, particularly when discomfort arises from reduced blood supply.

Eligibility and Restrictions for Use

Eligibility for Trimiron Use: Official Regulatory Information

Regulatory labeling strictly defines the patient populations permitted to use Trimiron and those who must not. This eligibility is determined by age, medical comorbidities, physiological state, and known hypersensitivity.

Contraindications (Must NOT Use):

  • Hypersensitivity: Patients with a known allergy to the active substance or any non-active ingredients are absolutely prohibited from using Trimiron.
  • Severe Organ Impairment: Use is contraindicated in individuals with severe, defined impairment of liver (hepatic failure) or kidney (renal failure) function, as drug clearance is compromised.
  • Specific Conditions: Exclusion applies to patients with a recent heart attack, certain cardiac conduction abnormalities, or conditions like G6PD deficiency or acute porphyria, due to defined safety risks.

Restricted or Conditional Use:

  • Age: The medicine is generally approved for use in Adults (18–65 years). Use in Older Adults (aged 65 and over) and Children/Adolescents requires special caution, often necessitating a reduced initial dose or specific monitoring due to altered drug metabolism and established data limitations.
  • Pregnancy and Lactation: Use during pregnancy is generally not recommended unless the potential benefit justifies the clear risks. Likewise, use is not recommended while breastfeeding as the drug may pass into breast milk.
  • Moderate Organ Impairment: Patients with mild to moderate kidney or liver impairment may use the medicine, but only under conditions requiring mandatory dose adjustments and close clinical monitoring.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Trimiron


Interaction Scope

Category Official Regulatory Information
Medicinal product categories with documented interactions Hepatic enzyme-inducing medicines, specific Hepatitis C drug regimens, and certain antiepileptic agents.
Specific interacting medicines (if explicitly listed) Rifampin, Phenytoin, Phenobarbital, Carbamazepine, and ombitasvir/paritaprevir/ritonavir drug regimens.
Mechanistic basis of interactions (only if stated in label) Hepatic enzyme induction leading to reduced hormone exposure. Metabolic inhibition of co-administered drugs.
Timing-based interaction rules (if applicable) None explicitly stated as mandatory separation timing rules.
Population-specific interaction notes (if applicable) The combination of use with tobacco smoking is contraindicated in women over 35 years of age due to increased cardiovascular risk.
Interaction-related restrictions Use with certain Hepatitis C drug combinations is contraindicated. Tobacco smoking is a major use restriction.

Interaction Classifications (High-Level)

Classification Official Regulatory Information
Interaction severity classification Contraindicated (with specific drug regimens); Reduced Efficacy Risk (with enzyme inducers); Use Restriction (with tobacco smoking).
Regulatory basis FDA/DailyMed, NIH/MedlinePlus, EMA documents.
Interaction-context constraints Interaction risk with smoking is constrained by patient age.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration is contraindicated with combination drug regimens for Hepatitis C containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the documented risk of liver enzyme elevations.
  • The use of hepatic enzyme-inducing drugs, such as Phenytoin and Rifampin, is documented to reduce the exposure of the hormonal components, which may result in loss of efficacy.
  • The medicine may inhibit the metabolism of co-administered drugs and increase their plasma concentrations.
  • The combination of use with tobacco smoking is contraindicated in women over 35 years of age due to the documented risk of serious cardiovascular events.
  • The interaction with Grapefruit Juice is documented to potentially increase the plasma concentration of the estrogen component.

Connection to the overall interaction profile (2–4 sentences): The official regulatory documentation defines this product's interaction structure primarily through pharmacokinetic changes, citing specific enzyme inducers that decrease hormone exposure and specific Hepatitis C regimens that are contraindicated due to risk of liver enzyme elevation. The profile also includes a critical regulatory restriction related to a substance interaction (tobacco) where the age of the patient is a mandated factor. This structure explicitly delineates prohibited combinations and interactions that result in reduced efficacy or increased risk, based strictly on government-verified data.

Mechanism of Action

Dual-Action Modulation of Gastrointestinal Motility

Trimiron functions as an agonist at the peripheral mu (mu), kappa (kappa), and delta (delta) opioid receptors primarily located within the enteric nervous system (ENS). This receptor binding modulates the release of key neurotransmitters, regulating the complex patterns of peristalsis and intestinal muscle tone, through which the drug influences both reduced and increased peristaltic rates.

Antispasmodic Effect via Ion Channel Interference

The drug also exerts a direct antispasmodic effect on intestinal smooth muscle cells by interfering with cellular excitation mechanisms. It acts as an inhibitor of Voltage-dependent L-type Calcium Channels (Cav1.x). By reducing the essential influx of Ca^2+ required for muscle contraction, Trimiron induces relaxation, resulting in decreased intestinal smooth muscle contraction frequency and reduced muscular tone within the gut wall.

Influence on Visceral Sensory Signaling

Trimiron influences the system of visceral nociception where it modulates the threshold for afferent (sensory) signal transmission. The collective modulation of ENS activity and muscle tone reduces the intensity of afferent signals generated in the gut lining from mechanical stimuli. This action modifies the early molecular steps that shape systemic physiological response to mechanical stimuli.

Dosage and Administration Information

How Trimiron is Used: Official Administration Guidelines

Trimiron (Trimetazidine) is used according to specific, standardized instructions outlined in prescribing documents. The medication is an oral treatment, meaning it is taken by mouth, and its usage is structured around specific dosage forms, frequencies, and administration timing.

Official Administration and Dosing

The treatment schedule is determined by the formulation used, which is available in two main strengths of oral tablets:

Dosage Form Strength Frequency Administration Time Total Daily Dose
Conventional Tablet 20 mg Three times daily (TID) During meals 60 mg
Modified-Release (MR) Tablet 35 mg Twice daily (BID) During meals 70 mg

All oral forms are instructed to be taken during meals (with food).

Procedural and Population Constraints

The usage protocol includes specific steps for proper long-term administration. The treatment's benefit must be assessed after three months of use, and discontinuation is recommended if a response is not observed.

Special Population Adjustments

The prescribing labels mandate dose adjustments for certain patient groups:

  • Moderate Renal Impairment: Patients with creatinine clearance of 30–60 mL/min must receive a reduced daily dose, such as one 35 mg MR tablet once daily (35 mg total) or one 20 mg conventional tablet twice daily (40 mg total).
  • Pediatric Population (<18 years): Use is not established and is therefore not recommended due to a lack of data on safety and effectiveness.

Following these administration constraints, including the correct timing with food and required dose adjustments for reduced kidney function, ensures the medication is used according to standard protocols.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Trimiron

This section provides an accessible summary of the official clinical research and scientific evaluations concerning Trimiron (Trimetazidine), which was evaluated as an add-on therapy for stable angina pectoris. The information describes the scope of the clinical evaluation and the types of outcomes that were examined by researchers, without offering clinical advice, instructions, or making definitive claims about individual outcomes.


Evidence for Use in Stable Angina Pectoris

The evidence summary is drawn mainly from Randomized Controlled Trials (RCTs) and subsequent systematic reviews and meta-analyses. Trimiron was evaluated in adult patients whose angina symptoms were not adequately managed by first-line medications, such as beta-blockers, but still experienced persistent symptoms. Research examined outcomes related to physical discomfort and physiological strain. Researchers monitored changes in weekly angina attack frequency and the consumption of rescue nitrate medication. The evidence contributes to understanding symptom patterns in conditions involving periods of heightened symptoms.

Functional Outcomes and Symptom Measurements

Research also examined outcomes related to daily functioning or activity level, with studies assessing patient activity during exercise. These studies monitored physiological strain by using controlled tests where the patient’s exercise capacity was observed in some studies. Specific functional outcomes included total exercise duration and the time to reach the ischemia threshold during exercise. Studies report how these functional measurements changed in the observed populations, which helps contextualize how patients reported their experience.

Long-Term Evidence and Follow-Up Duration

While the core studies were relevant in trials assessing short-term or episodic patterns, their follow-up durations were typically limited, usually lasting only a few weeks to three months. Due to the chronic nature of stable angina, long-term effects are not fully established. Evidence is limited regarding the effect on major cardiovascular events. Findings were mixed across longer-term analyses, and the certainty remains low regarding the full impact on hard outcomes such as cardiac events or mortality.

Evidence in Specific Patient Groups

The principal study populations generally included adults with stable angina whose conditions were characterized by fluctuating or episodic manifestations. Research also examined specific cohorts, including patients with coexisting Type 2 Diabetes Mellitus, with studies monitoring outcomes over defined time intervals. Comparative evidence for certain other demographic subgroups remains insufficient.

What is Still Uncertain About Trimiron's Research Base

The overall research provides context but not individual predictions. Evidence highlights what is known — and what is still uncertain. Evidence is limited regarding the medicine's potential impact on major clinical events, such as hospitalizations or mortality, with some large studies reporting mixed findings. The evidence base includes older studies where regulatory reviews noted that the evidence quality varies due to acknowledged methodological constraints. Research does not determine whether an individual will respond similarly, and data for certain groups remain insufficient, particularly those with complex or rare comorbidities.

Key Studies & References

  1. Trimetazidine in the management of stable angina: a systematic review of clinical trials

Frequently Asked Questions (FAQ)

Common questions about Trimiron (FAQ)


Q: How long does it typically take to feel the effects of Trimiron?

According to the official product information, for its primary purpose of contraception, the medicine requires at least 7 days of continuous use before the medicine is expected to be effective. A non-hormonal backup method is often mentioned in official documentation for use during this initial period.


Q: How long does Trimiron stay in your system after stopping?

Official pharmacological data describes how the body processes the medicine. The two active components have elimination half-lives of approximately 38 hours and 26 hours, respectively, once a steady level is reached. The half-life is the time needed for the amount of medicine in the body to decrease by half.


Q: Can taking vitamins or supplements affect Trimiron?

Official information indicates that the use of hormonal contraceptives can influence the body's levels of certain nutrients, such as B vitamins and Folic Acid. Interactions with certain herbal products are also a documented possibility. The regulatory documentation advises that the use of all supplements, vitamins, and herbs be disclosed.


Q: What should I know about switching from another drug to Trimiron?

Official guidelines mention that when switching from another contraceptive method, use can often be started at any point in the cycle if pregnancy has been excluded. For certain starting methods, the label specifies the need for a non-hormonal barrier method for the first 7 days to maintain expected effectiveness.


Q: How quickly do the side effects of Trimiron usually appear?

Common effects like headache, nausea, or breast tenderness are most frequently reported during the first few months after starting use. Official documentation also notes that the risk of rare, serious events is highest during the first year of use or when re-initiating the medicine after a long break.


Q: Can people with kidney or liver problems use Trimiron?

Official regulatory information strictly contraindicates the use of this medicine in individuals with severe, defined liver disease or kidney failure. The label describes conditions for use in individuals with mild to moderate impairment, stating that its use requires specific dose considerations and close clinical monitoring.


Q: How is Trimiron different from similar medications?

The medicine contains the progestin desogestrel, which is categorized as a third-generation progestogen. Official pharmacological information notes that its active metabolite has high progestational activity combined with minimal intrinsic androgenicity, a characteristic that differentiates it from some older progestin compounds.


Q: Can Trimiron cause problems with sleeping?

According to the official safety profile, difficulty in sleeping (insomnia) is listed as one of the possible side effects that have been reported by users of this medicine.


Q: Has Trimiron been approved in many countries?

Studies and official information indicate that the medicine and its generic forms are regulated and approved by key governmental authorities in major global regions, including the US Food and Drug Administration (FDA) and European regulatory bodies.


Q: Are there long-term side effects noted in the research for Trimiron?

Regulatory documents list certain adverse reactions reported by users over time, including changes in corneal curvature, intolerance to contact lenses, and possible changes in appetite. Official safety documentation notes that for some of these reported events, a confirmed causal link has not been definitively established.


Q: Why is the mechanism of action for Trimiron described as it is?

The description of the medicine's mechanism is strictly based on the results of clinical and pharmacological studies. These studies evaluated its primary purpose of suppressing gonadotropins and the resulting physical alterations in cervical mucus and the uterine lining.


Q: If I have mild side effects, is that normal for Trimiron?

The official safety documentation classifies many effects based on how frequently they are reported. Common effects such as headache, nausea, breast tenderness, and mood changes are classified as frequently occurring events.


Q: Is there a certain time of day that is best for taking Trimiron?

Official instructions advise that the medicine be taken at the same time each day for consistent use and expected effectiveness. Regulatory documents do not mandate a specific time of day, only that the time be consistent.


Q: What are the signs that Trimiron is not working for someone?

The primary purpose of the medicine is the prevention of pregnancy. A lack of the intended therapeutic effect, which may be indicated by a lack of expected cycle control, persistent spotting or bleeding, or the occurrence of pregnancy, could be a sign of non-response.


Q: Can Trimiron cause feelings of dizziness or lightheadedness?

Dizziness is listed as one of the possible adverse reactions that have been reported by users of this medicine in official safety documents.


Q: Does Trimiron interact with herbal teas or natural remedies?

Regulatory documentation advises that the use of all medications, including vitamins and herbs, be reported. Interactions with herbal products or natural remedies are a documented possibility for hormonal contraceptives, particularly those that affect the body's metabolism.


Q: Are there any known issues with Trimiron and sun exposure?

The risk of melasma, a type of skin darkening or hyperpigmentation that may be worsened by exposure to sunlight, has been reported in users of this medicine.


Q: Does Trimiron affect mental clarity or focus?

The official safety profile notes possible changes in mood, nervousness, and lack of energy as reported side effects. These are classified as events that may occur during use.

How should Trimiron be stored and disposed of?

How to Store and Dispose of Trimiron

The storage and disposal instructions for Trimiron (Trimetazidine) are strictly defined by regulatory labeling to maintain the product's quality and ensure public safety.

Mandatory Storage Conditions

Condition Requirement
Temperature Store at a temperature not exceeding 30 C.
Environment Do not refrigerate or freeze the medicine.
Packaging Keep the tablets in the original package (blister and outer carton) to protect them from moisture and until the labeled expiry date.
Child Safety Keep this medicine out of the sight and reach of children.

Official Disposal Rules

To protect the environment, the official labeling requires that unused or expired Trimiron must not be thrown away via wastewater or household waste. The proper disposal procedure involves returning the unused medicine to a pharmacist, who is equipped to discard it in accordance with local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trimiron found in:

A-Z Index: